LUNDBECK
Valby,
Wednesday,
The annual general meeting will be held at the offices of the Company at:
Agenda
In accordance with Article 8.1 of the Articles of Association, the agenda of the meeting is as follows:
1. Report of the Board of Directors on the Company's activities during the past year.
2. Presentation and adoption of the annual report.
3. Resolution on the appropriation of profit or loss as recorded in the adopted annual report.
4. Presentation of and advisory vote on the remuneration report.
5. Election of members to the Board of Directors.
6. Approval of remuneration for the Board of Directors for the current financial year.
7. Election of one or two state-authorized public accountants.
8. Any proposals by shareholders or the Board of Directors:
1. Proposal from the Board of Directors to authorize the Board of Directors to allow the Company to acquire treasury shares.
2. Proposal from the Board of Directors to authorize the Chairman of the meeting to file the resolutions passed at the annual general meeting for registration with the
9. Any other business.
Contact:
Investors
Vice President
Investor Relations
E: PALO@lundbeck.com
T: +45 30 83 24 26
Media
Media Relations Lead
Corp. Communication
E: THMR@lundbeck.com
T: +45 30 83 30 24
About
Lundbeck is a global pharmaceutical company specialized in brain diseases. For more than 70 years, we have been at the forefront of neuroscience research. We are tirelessly dedicated to restoring brain health, so every person can be their best. We are committed to fighting stigma and discrimination against people living with brain diseases and advocating for broader social acceptance of people with brain health conditions. Our research programs tackle some of the most complex challenges in neuroscience, and our pipeline is focused on bringing forward transformative treatments for brain diseases for which there are few, if any therapeutic options.
For additional information, we encourage you to visit our corporate site?www.lundbeck.com?and connect with us on Instagram (h_lundbeck), Twitter at?@Lundbeck?and via?LinkedIn.
Safe Harbor/Forward-Looking Statements
This corporate release contains forward-looking statements that provide our expectations or forecasts of future events such as new product introductions, product approvals and financial performance. Forward looking statements include, without limitation, any statement that may predict, forecast, indicate or imply future results, performance or achievements, and may contain words like 'believe', 'anticipate', 'expect', 'estimate', 'intend', 'plan', 'project', 'will be', 'will continue', 'will result', 'could', 'may', 'might', or any variations of such words or other words with similar meanings. All statements other than statements of historical facts included in this presentation, including, without limitation, those regarding our financial position, business strategy, plans and objectives of management for future operations (including development plans and objectives relating to our products), are forward looking statements.
Such forward looking statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward looking statements. Factors that may affect future results include, among others, interest rate and currency exchange rate fluctuations, delay or failure of development projects, production or distribution problems, unexpected contract breaches or terminations, government-mandated or market-driven price decreases for Lundbeck's products, introduction of competing products, Lundbeck's ability to successfully market both new and existing products, exposure to product liability and other lawsuits, changes in reimbursement rules and governmental laws and related interpretation thereof, and unexpected growth in costs and expenses.
The forward-looking statements in this document and oral presentations made on behalf of Lundbeck speak only as at the date of this presentation. Lundbeck does not undertake any obligation to update or revise forward-looking statements in this presentation or oral presentations made on behalf of Lundbeck, nor to confirm such statements to reflect subsequent events or circumstances after the date of the presentation or in relation to actual results, unless otherwise required by applicable law or applicable stock exchange regulations.
Contact:
Ottiliavej 9, 2500 Valby
T: +45 3630 1311
E: info@lundbeck.com
(C) 2022 Electronic News Publishing, source
